Summary
Global Sexually Transmitted Diseases (STD) Diagnostics Market was valued at USD 90.75 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.54% through 2029. The Sexually Transmitted Diseases (STD) Diagnostics Market refers to the sector involved in the development, production, and distribution of various diagnostic tools and procedures to detect sexually transmitted diseases. These include, but are not limited to, laboratory devices, testing kits, and digital solutions. The market size and trends are influenced by many factors such as prevalence and incidence rates of STDs, technological advancements in diagnostics, and health awareness and education initiatives.
Key Market Drivers
Increase in Multiplex Assays for Multiple Pathogens
Multiplex assays detect multiple Sexually Transmitted Diseases (STD)s in a single test, eliminating the need for multiple separate tests, saving time and money. By detecting multiple Sexually Transmitted Diseases (STD)s at once, multiplex assays provide a complete picture of an individual’s infection status, allowing for faster and more targeted treatment decisions. These provide high sensitivity and specificity for pathogen detection. Multiplex assays use high-throughput molecular assays, including nucleic acid amplification (NAA), to amplify and detect DNA or RNA sequences related to the targeted Sexually Transmitted Diseases (STD)s. This high sensitivity guarantees accurate detection, even in low-pathogen concentrations, while ensuring specificity to reduce false-positive results. Multiplex assays cover a broad spectrum of sexually transmitted infections (Sexually Transmitted Diseases (STD)s) in one test. Multiplex assays are designed to detect a variety of bacterial, viral, and parasitic pathogens related to sexually transmitted diseases (Sexually Transmitted Diseases (STD)s). Some of the pathogens that can be detected in a multiplex test include Chlamydia Trachomatis, Neisseria Gonorrhoeae, Trichomonas Vaginalis, Human Papillomavirus, Herpes Simplex Virus (HSV), Treponema Pallidum Syphilis. By combining multiple assays into a single test, this allows for more efficient use of resources in a laboratory setting. Multiplex assays require less sample volume. This reduces the need for further sample collection and reduces the patient burden. Multiplex assays reduce the workload of laboratory staff. This reduces the time and resources needed to perform and interpret multiple individual tests. Multiplex assays provide a quicker turnaround time compared to performing multiple individual tests. Draft global health sector guidelines on Sexually Transmitted Diseases (Sexually Transmitted Diseases (STD)s) Developed in line with the 2030 Agenda for Sustainable Development by WHO.
Multiple pathogens detected in a single assay speed up the diagnostic process, allowing for faster diagnosis and treatment initiation. This is especially important in clinical settings where fast diagnosis is critical for patient care and public health interventions. Multiplex assays are important for surveillance and epidemiology studies. Multiplex assays detect multiple pathogens in one test, allowing for a better understanding of a population’s prevalence of Sexually Transmitted Diseases (STD)s, co-infection, and transmission patterns. This information is used to inform public health policies, interventions, and the allocation of resources for disease control and prevention. This factor will help in the growth of Global Sexually Transmitted Diseases (STD) Diagnostics Market.
Increased Demand of Home-Based Diagnostic Kits
Home-based Sexually Transmitted Diseases (STD) kits provide convenience and privacy for people who want to test for sexually transmitted diseases (Sexually Transmitted Diseases (STD)s) in the privacy of their own home. They also eliminate the need to go to the clinic or have an in-person appointment, which can be less discreet and less convenient for some people. One of the biggest benefits of home-based kits is that they can provide more access to testing for Sexually Transmitted Diseases (STD)s, especially for those who may not have access to traditional healthcare services, such as those living in rural areas, those with limited mobility or those who are afraid or embarrassed to go to a clinic for testing. Depending on the type of Sexually Transmitted Diseases (STD) being tested, home-based kits include step-by-step instructions and materials to collect a sample (e.g., urine sample, blood sample, swab sample). The sample is then shipped or sent to a lab or processing facility for analysis.
Depending on the type of Sexually Transmitted Diseases (STD)s being tested and the technology included in the kit, home-based Sexually Transmitted Diseases (STD) diagnostic kits may use rapid antigen or antibody testing (PAATs), nucleic acid amplification (NAATs) or other laboratory methods. The purpose of home-based Sexually Transmitted Diseases (STD) kits is to test for Sexually Transmitted Diseases (STD)s and provide results that are accurate and reliable. However, the accuracy of home-based kits can vary and may have a slightly higher chance of false positives or false negatives compared to tests done in a clinical lab. Therefore, it is important that you follow the instructions and think about confirmatory testing if you have any doubts or questions about the results. Some home-based STI kits also include counseling services or a helpline for people who may need help or advice before or after the test. These may include information on the consequences of the test, advice on what to do next, and resources for continuing care or treatment. This factor will pace up the demand of global sexually transmitted diseases (STD) diagnostics market.
Increase in Prevalence of STDs
The global increase in the prevalence of sexually transmitted diseases (STDs) is driving a surge in demand for STD diagnostics on a broad scale. As public health concerns intensify, and awareness campaigns gain momentum, individuals are becoming more proactive about their sexual health, leading to a higher demand for accurate and timely diagnostics. The rising incidence of STDs, including but not limited to chlamydia, gonorrhea, and syphilis, necessitates robust diagnostic tools to facilitate early detection and effective treatment. Healthcare providers are responding to this growing demand by integrating advanced diagnostic technologies, such as nucleic acid amplification tests (NAATs), rapid point-of-care tests, and serological assays.
Additionally, increased accessibility to healthcare services, especially in developing regions, is contributing to a broader reach for STD diagnostics. The globalized nature of travel and lifestyle choices also plays a role, as individuals seek testing services for STDs with greater frequency. This burgeoning demand is fostering innovation within the diagnostics industry, prompting collaborations between healthcare institutions and diagnostic manufacturers to develop more sensitive, specific, and user-friendly diagnostic tools. As the global community continues to prioritize sexual health, the upward trajectory in demand for STD diagnostics is expected to persist, shaping the future landscape of STD management and prevention worldwide.
Rise in Government Initiatives for STD Testing
The global demand for Sexually Transmitted Diseases (STD) diagnostics is experiencing a substantial upswing, driven by the rise in government initiatives aimed at promoting and expanding STD testing worldwide. Recognizing the public health implications of STDs, governments across the globe are actively implementing programs to raise awareness, reduce stigma, and enhance access to testing services. The increased emphasis on preventative healthcare and early intervention has spurred a growing demand for reliable and efficient diagnostic tools. Governments are investing in comprehensive STD testing campaigns, offering free or subsidized testing services, and establishing dedicated clinics and outreach programs. These initiatives not only cater to high-risk populations but also encourage a broader segment of the population to undergo regular testing, contributing to the overall increase in demand for STD diagnostics.
Furthermore, public-private partnerships are emerging to support government efforts, fostering innovation in diagnostic technologies and ensuring widespread accessibility. As a result, the global diagnostic industry is witnessing a surge in research, development, and production of advanced STD diagnostic tools, including rapid tests, molecular assays, and point-of-care devices. The combined efforts of governments and industry stakeholders are reshaping the landscape of STD testing, underscoring the importance of proactive healthcare measures in the global fight against the spread of sexually transmitted diseases.
Key Market Challenges
Inadequate Health Infrastructure
The global demand for Sexually Transmitted Diseases (STD) diagnostics faces a decline due to the pervasive challenge of inadequate health infrastructure on a global scale. In regions with limited healthcare resources, particularly in low-income areas, the ability to meet the demand for comprehensive STD diagnostics is hindered. The lack of accessible healthcare facilities and trained personnel contributes to delayed or missed opportunities for testing and diagnosis. Individuals in these areas often face barriers to seeking timely healthcare services, including STD diagnostics, resulting in underdiagnosed and untreated cases.
The demand for diagnostic tests is adversely affected by the scarcity of testing facilities and the overall inability of health systems to address the growing prevalence of STDs. To reverse this trend, there is an urgent need for substantial investments in healthcare infrastructure, training programs for healthcare professionals, and the establishment of testing centers in underserved regions. Collaborative efforts between governments, non-governmental organizations, and industry stakeholders are essential to bridge the gap and ensure that STD diagnostics become more accessible and integrated into healthcare systems globally. Addressing the inadequacies in health infrastructure is crucial to meet the growing demand for STD diagnostics and to effectively combat the spread of sexually transmitted diseases.
Limited Access to Diagnostic Tests
The global demand for Sexually Transmitted Diseases (STD) diagnostics is facing a notable decline due to limited access to diagnostic tests on a global scale. In various regions, particularly those with underdeveloped healthcare systems, there is a pervasive lack of accessibility to comprehensive STD testing. Individuals in these areas encounter significant barriers, including geographic remoteness, financial constraints, and the absence of well-established healthcare infrastructure. Limited access to diagnostic tests contributes to delayed or missed opportunities for early detection and treatment of STDs, leading to increased transmission rates and long-term health complications.
The demand for STD diagnostics is adversely affected as a result of these challenges, with individuals often unable to undergo routine screenings or seek timely medical attention. To address this issue, concerted efforts are required to expand the reach of diagnostic services through initiatives such as mobile clinics, community outreach programs, and affordable testing options. Collaboration between public health organizations, governments, and diagnostic manufacturers is crucial to develop strategies that overcome these accessibility barriers and enhance the availability of STD diagnostic tests globally. By prioritizing solutions that improve access, the healthcare industry can effectively address the decreasing demand for STD diagnostics and contribute to the broader goal of controlling the spread of sexually transmitted diseases.
Key Market Trends
Advancements in PCR (Polymerase Chain Reaction) Testing
The global demand for Sexually Transmitted Diseases (STD) diagnostics is on the rise due to the pervasive issue of inadequate health infrastructure worldwide. Insufficient healthcare facilities and resources, particularly in low-income and underserved regions, pose significant challenges in addressing the growing prevalence of STDs. In the face of limited access to comprehensive healthcare services, individuals may lack timely and affordable access to STD testing. The shortage of testing facilities and trained healthcare professionals exacerbates the problem, resulting in delayed or underdiagnosed cases. The pressing need to bridge this healthcare gap has led to an increased demand for portable and user-friendly STD diagnostics that can be deployed in resource-constrained settings. Rapid tests, point-of-care diagnostics, and other innovative solutions are becoming crucial tools in overcoming the limitations imposed by inadequate health infrastructure.
Additionally, the global community's recognition of the role of diagnostics in preventing the spread of STDs has spurred collaborations between public health organizations, governments, and diagnostic manufacturers to develop strategies and technologies that can address the diagnostic needs in diverse and challenging environments. As efforts intensify to strengthen health systems globally, the demand for STD diagnostics is expected to persist, reflecting the urgency of providing accessible and effective testing solutions in regions facing infrastructural constraints.
Development of Rapid Diagnostic Tests
The global demand for Sexually Transmitted Diseases (STD) diagnostics is experiencing a significant upswing, driven by the rapid development of diagnostic technologies, particularly in the realm of rapid diagnostic tests (RDTs). The introduction of user-friendly, point-of-care STD diagnostics has revolutionized the landscape, offering quick and accurate results without the need for extensive laboratory infrastructure. These RDTs, capable of providing results within minutes, are instrumental in overcoming barriers to testing accessibility, especially in remote or resource-limited settings. The emphasis on early detection and prompt treatment of STDs has heightened the demand for these rapid tests, as they empower healthcare professionals to swiftly initiate interventions and reduce the risk of further transmission. Additionally, the convenience and efficiency of RDTs resonate with a global population increasingly focused on proactive healthcare measures.
The market response to the surge in demand has prompted ongoing innovation, with companies investing in research and development to enhance the sensitivity and specificity of rapid STD diagnostic tests. This trend is fostering collaborations between healthcare providers, regulatory bodies, and industry stakeholders, shaping the landscape of STD diagnostics and ensuring that these crucial tools are more widely available and accessible on a global scale. The development of RDTs is not only meeting the current demand for STD diagnostics but is also poised to play a pivotal role in shaping the future of point-of-care diagnostics across various healthcare domains.
Segmental Insights
Product Insights
Based on the product, the global sexually transmitted diseases (std) diagnostics market is currently dominated by the instruments and services segment. This can be attributed to the need for reliable, accurate, and rapid diagnostic platforms which are essential in preventing the spread of these diseases. Meanwhile, consumables and software also play vital roles in the market, but they do not lead in terms of market share. Furthermore, the rise in public health awareness programs and initiatives aimed at promoting STD screening and prevention has increased the demand for diagnostic services. Healthcare facilities, clinics, and laboratories rely on specialized services for STD testing, including sample collection, processing, and interpretation of test results. This has led to a significant expansion of diagnostic service offerings in the market.
Moreover, the increasing adoption of point-of-care testing (POCT) solutions for STD diagnostics has further fuelled the growth of the instruments and services segment. POCT instruments offer convenience, accessibility, and rapid results, making them particularly suitable for resource-limited settings and decentralized healthcare settings.
Application Insights
Based on the application segment,Chlamydia Trachomatis_andNeisseria Gonorrhoeae_(CT/NG) testing is currently leading the global sexually transmitted diseases (STD) diagnostics market. This is due to an increase in the prevalence of these diseases and the availability of cost-effective diagnostic kits. Nonetheless, aspects such as regional prevalence, governmental policies, and accessibility to testing facilities can impact the leading position in different global regions.
CT/NG infections often present with asymptomatic or mild symptoms, leading to underdiagnosis and undertreatment. This underscores the importance of routine screening and testing for Chlamydia trachomatis and Neisseria gonorrhoeae, especially among sexually active individuals and high-risk populations. Healthcare providers prioritize CT/NG testing as part of comprehensive STD screening protocols to identify and treat infections promptly, thereby preventing complications and transmission. Furthermore, advancements in diagnostic technologies have led to the development of highly sensitive and specific tests for Chlamydia trachomatis and Neisseria gonorrhoeae detection. These include nucleic acid amplification tests (NAATs), such as polymerase chain reaction (PCR) and transcription-mediated amplification (TMA), which offer excellent accuracy and can detect low levels of bacterial DNA or RNA in clinical samples.
Regional Insights
In the global sexually transmitted diseases (STD) diagnostics market, North America is currently leading the way. This dominance can be attributed to several factors. The region has a higher prevalence of STDs, which necessitates a robust diagnostic market. North America boasts advanced healthcare infrastructure, enabling efficient diagnosis and treatment of STDs. Additionally, there is heightened awareness and emphasis on sexual health in this region, leading to increased demand for diagnostic services. North America benefits from the availability of sophisticated and cutting-edge diagnostic tools, further enhancing the accuracy and effectiveness of STD diagnostics. Collectively, these factors contribute to North America's unrivaled position in the global STD diagnostics market.
Key Market Players
Becton Dickinson and Company
F. Hoffmann-La Roche Ltd.
Hologic, Inc.
bioMérieux S.A.
Abbott Laboratories Inc.
Danaher Corporation
Qiagen N.V.
Thermo Fisher Scientific Inc.
DiaSorin S.p.A
Bio-Rad Laboratories, Inc.
Report Scope:
In this report, the Global Sexually Transmitted Diseases (STD) Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Sexually Transmitted Diseases (STD) Diagnostics Market,By Product:
oInstruments and Services
oConsumables
oSoftware
Sexually Transmitted Diseases (STD) Diagnostics Market,By Application:
oHIV Testing
oHSV Testing
oCT/NG testing
oSyphilis testing
oGonorrhea testing
oOthers
Sexually Transmitted Diseases (STD) Diagnostics Market,By Technology:
oImmunoassay
oMolecular Diagnostics
oOthers
Sexually Transmitted Diseases (STD) Diagnostics Market,By Location of Testing:
oLaboratory Testing
oPoint of Care Testing
oOthers
Sexually Transmitted Diseases (STD) Diagnostics Market, By Region:
oNorth America
§United States
§Canada
§Mexico
oEurope
§France
§United Kingdom
§Italy
§Germany
§Spain
oAsia-Pacific
§China
§India
§Japan
§Australia
§South Korea
oSouth America
§Brazil
§Argentina
§Colombia
oMiddle East Africa
§South Africa
§Saudi Arabia
§UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Sexually Transmitted Diseases (STD) Diagnostics Market.
Available Customizations:
Global Sexually Transmitted Diseases (STD) Diagnostics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
ページTOPに戻る
Table of Contents
1.Product Overview
1.1.Market Definition
1.2.Scope of the Market
1.2.1.Markets Covered
1.2.2.Years Considered for Study
1.2.3.Key Market Segmentations
2.Research Methodology
2.1.Objective of the Study
2.2.Baseline Methodology
2.3.Key Industry Partners
2.4.Major Association and Secondary Sources
2.5.Forecasting Methodology
2.6.Data Triangulation Validations
2.7.Assumptions and Limitations
3.Executive Summary
3.1.Overview of the Market
3.2.Overview of Key Market Segmentations
3.3.Overview of Key Market Players
3.4.Overview of Key Regions/Countries
3.5.Overview of Market Drivers, Challenges, Trends
4.Voice of Customer
5.Global Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
5.1.Market Size Forecast
5.1.1.By Value
5.2.Market Share Forecast
5.2.1.By Product (Instruments and Services, Consumables, Software)
5.2.2.By Application (HIV Testing, HSV Testing, CT/NG testing, Syphilis testing, Gonorrhea testing, Others)
5.2.3.By Technology (Immunoassay, Molecular Diagnostics, Others)
5.2.4.By Location of Testing (Laboratory Testing, Point of Care Testing, Others)
5.2.5.By Region
5.2.6.By Company (2023)
5.3.Market Map
6.North America Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
6.1.Market Size Forecast
6.1.1.By Value
6.2.Market Share Forecast
6.2.1.By Product
6.2.2.By Application
6.2.3.By Technology
6.2.4.By Location of Testing
6.2.5.By Country
6.3.North America: Country Analysis
6.3.1.United States Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
6.3.1.1.Market Size Forecast
6.3.1.1.1.By Value
6.3.1.2.Market Share Forecast
6.3.1.2.1.By Product
6.3.1.2.2.By Application
6.3.1.2.3.By Technology
6.3.1.2.4.By Location of Testing
6.3.2.Canada Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
6.3.2.1.Market Size Forecast
6.3.2.1.1.By Value
6.3.2.2.Market Share Forecast
6.3.2.2.1.By Product
6.3.2.2.2.By Application
6.3.2.2.3.By Technology
6.3.2.2.4.By Location of Testing
6.3.3.Mexico Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
6.3.3.1.Market Size Forecast
6.3.3.1.1.By Value
6.3.3.2.Market Share Forecast
6.3.3.2.1.By Product
6.3.3.2.2.By Application
6.3.3.2.3.By Technology
6.3.3.2.4.By Location of Testing
7.Europe Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
7.1.Market Size Forecast
7.1.1.By Value
7.2.Market Share Forecast
7.2.1.By Product
7.2.2.By Application
7.2.3.By Technology
7.2.4.By Location of Testing
7.2.5.By Country
7.3.Europe: Country Analysis
7.3.1.France Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
7.3.1.1.Market Size Forecast
7.3.1.1.1.By Value
7.3.1.2.Market Share Forecast
7.3.1.2.1.By Product
7.3.1.2.2.By Application
7.3.1.2.3.By Technology
7.3.1.2.4.By Location of Testing
7.3.2.Germany Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
7.3.2.1.Market Size Forecast
7.3.2.1.1.By Value
7.3.2.2.Market Share Forecast
7.3.2.2.1.By Product
7.3.2.2.2.By Application
7.3.2.2.3.By Technology
7.3.2.2.4.By Location of Testing
7.3.3.United Kingdom Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
7.3.3.1.Market Size Forecast
7.3.3.1.1.By Value
7.3.3.2.Market Share Forecasty
7.3.3.2.1.By Product
7.3.3.2.2.By Application
7.3.3.2.3.By Technology
7.3.3.2.4.By Location of Testing
7.3.4.Italy Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
7.3.4.1.Market Size Forecast
7.3.4.1.1.By Value
7.3.4.2.Market Share Forecast
7.3.4.2.1.By Product
7.3.4.2.2.By Application
7.3.4.2.3.By Technology
7.3.4.2.4.By Location of Testing
7.3.5.Spain Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
7.3.5.1.Market Size Forecast
7.3.5.1.1.By Value
7.3.5.2.Market Share Forecast
7.3.5.2.1.By Product
7.3.5.2.2.By Application
7.3.5.2.3.By Technology
7.3.5.2.4.By Location of Testing
8.Asia-Pacific Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
8.1.Market Size Forecast
8.1.1.By Value
8.2.Market Share Forecast
8.2.1.By Product
8.2.2.By Application
8.2.3.By Technology
8.2.4.By Location of Testing
8.2.5.By Country
8.3.Asia-Pacific: Country Analysis
8.3.1.India Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
8.3.1.1.Market Size Forecast
8.3.1.1.1.By Value
8.3.1.2.Market Share Forecast
8.3.1.2.1.By Product
8.3.1.2.2.By Application
8.3.1.2.3.By Technology
8.3.1.2.4.By Location of Testing
8.3.2.China Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
8.3.2.1.Market Size Forecast
8.3.2.1.1.By Value
8.3.2.2.Market Share Forecast
8.3.2.2.1.By Product
8.3.2.2.2.By Application
8.3.2.2.3.By Technology
8.3.2.2.4.By Location of Testing
8.3.3.South Korea Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
8.3.3.1.Market Size Forecast
8.3.3.1.1.By Value
8.3.3.2.Market Share Forecast
8.3.3.2.1.By Product
8.3.3.2.2.By Application
8.3.3.2.3.By Technology
8.3.3.2.4.By Location of Testing
8.3.4.Australia Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
8.3.4.1.Market Size Forecast
8.3.4.1.1.By Value
8.3.4.2.Market Share Forecast
8.3.4.2.1.By Product
8.3.4.2.2.By Application
8.3.4.2.3.By Technology
8.3.4.2.4.By Location of Testing
8.3.5.Japan Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
8.3.5.1.Market Size Forecast
8.3.5.1.1.By Value
8.3.5.2.Market Share Forecast
8.3.5.2.1.By Product
8.3.5.2.2.By Application
8.3.5.2.3.By Technology
8.3.5.2.4.By Location of Testing
9.South America Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
9.1.Market Size Forecast
9.1.1.By Value
9.2.Market Share Forecast
9.2.1.By Product
9.2.2.By Application
9.2.3.By Technology
9.2.4.By Location of Testing
9.2.5.By Country
9.3.South America: Country Analysis
9.3.1.Brazil Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
9.3.1.1.Market Size Forecast
9.3.1.1.1.By Value
9.3.1.2.Market Share Forecast
9.3.1.2.1.By Product
9.3.1.2.2.By Application
9.3.1.2.3.By Technology
9.3.1.2.4.By Location of Testing
9.3.2.Argentina Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
9.3.2.1.Market Size Forecast
9.3.2.1.1.By Value
9.3.2.2.Market Share Forecast
9.3.2.2.1.By Product
9.3.2.2.2.By Application
9.3.2.2.3.By Technology
9.3.2.2.4.By Location of Testing
9.3.3.Colombia Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
9.3.3.1.Market Size Forecast
9.3.3.1.1.By Value
9.3.3.2.Market Share Forecast
9.3.3.2.1.By Product
9.3.3.2.2.By Application
9.3.3.2.3.By Technology
9.3.3.2.4.By Location of Testing
10.Middle East and Africa Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
10.1.Market Size Forecast
10.1.1.By Value
10.2.Market Share Forecast
10.2.1.By Product
10.2.2.By Application
10.2.3.By Technology
10.2.4.By Location of Testing
10.2.5.By Country
10.3.MEA: Country Analysis
10.3.1.South Africa Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
10.3.1.1.Market Size Forecast
10.3.1.1.1.By Value
10.3.1.2.Market Share Forecast
10.3.1.2.1.By Product
10.3.1.2.2.By Application
10.3.1.2.3.By Technology
10.3.1.2.4.By Location of Testing
10.3.2.Saudi Arabia Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
10.3.2.1.Market Size Forecast
10.3.2.1.1.By Value
10.3.2.2.Market Share Forecast
10.3.2.2.1.By Product
10.3.2.2.2.By Application
10.3.2.2.3.By Technology
10.3.2.2.4.By Location of Testing
10.3.3.UAE Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
10.3.3.1.Market Size Forecast
10.3.3.1.1.By Value
10.3.3.2.Market Share Forecast
10.3.3.2.1.By Product
10.3.3.2.2.By Application
10.3.3.2.3.By Technology
10.3.3.2.4.By Location of Testing
11.Market Dynamics
11.1.Drivers
11.2.Challenges
12.Market Trends Developments
12.1.Recent Development
12.2.Mergers Acquisitions
12.3.Product Launches
13.Global Sexually Transmitted Diseases (STD) Diagnostics Market: SWOT Analysis
14.Porter’s Five Forces Analysis
14.1.Competition in the Industry
14.2.Potential of New Entrants
14.3.Power of Suppliers
14.4.Power of Customers
14.5.Threat of Substitute Products
15.Competitive Landscape
15.1.Becton Dickinson and Company
15.1.1.Business Overview
15.1.2.Company Snapshot
15.1.3.Products Services
15.1.4.Financials (As Reported)
15.1.5.Recent Developments
15.1.6.Key Personnel Details
15.1.7.SWOT Analysis
15.2.F. Hoffmann-La Roche Ltd.
15.3.Hologic, Inc.
15.4.bioMérieux S.A.
15.5.Abbott Laboratories Inc.
15.6.Danaher Corporation
15.7.Qiagen N.V.
15.8.Thermo Fisher Scientific Inc.
15.9.DiaSorin S.p.A
15.10.Bio-Rad Laboratories, Inc.
16.Strategic Recommendations
17.About Us Disclaimer
